NEW TECHNOLOGY TO GUIDE FUTURE BOWEL CANCER TREATMENT Research capabilities within the Kolling Institute have
will measure molecules with very high accuracy, providing researchers with valuable and practical information about how bowel cancer develops. “Years ago we could measure 400-500 proteins within a sample, compared with more than 6,000 proteins now,” Mark said. “This means our data is more accurate and we have a clearer understanding of the molecular make-up of tumours. “We would like to see our research influence future bowel cancer treatment by
indicating which patients are at disease risk, which cancers will benefit from chemotherapy and radiotherapy, and which cancers are likely to recur,” Mark said. Mark’s research has been further boosted with a cheque for $500,000 from Bowel Cancer Research Foundation Australia. Chairman Richard Griffin said he was very confident it would lead to some remarkable and ground breaking research, and bring relief to so many people.
been significantly broadened with new technology to assist the examination of bowel cancer. Representatives from Sydney University, the Kolling and Bowel Cancer Australia attended the official opening of the mass spectrometry core lab – the first of its type on a hospital campus and one of the best analytical
facilities in the world. Professor Mark Molloy, Lawrence Penn chair of
Bowel Cancer Research said the sophisticated technology
ACCOLADES TO OUR CLINICAL RESEARCHERS Two of our researchers have won awards for their clinical research.
Evaluation Award for her work into “Minimising the Functional Burden of Medications in Older Inpatients: Implementation of the Drug Burden Index”. Sarah and her team are investigating polypharmacy in older patients and the effects of de-prescribing, with this particular project on the Drug Burden Index, funded by NSW Health’s Agency of Clinical Innovation. Royal North Shore-based rheumatologist Prof David Hunter was awarded the Clinical Research Award from the Osteoarthritis Research Society International. This is
the pre-eminent organisation internationally for this disease. Prof Anastasia Mihailidou has also been accepted as a Fellow of the Cardiac Society of Australia & New Zealand.
Professor Sarah Hilmer, who is a geriatrician and pharmacologist at Royal North Shore Hospital, picked up the Innovation Development and
7
Made with FlippingBook - professional solution for displaying marketing and sales documents online